Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

BridgeBio Pharma Inc. (BBIO)

NASDAQ: BBIO · Pharmaceutical Preparations · Palo Alto, CA

Our rating: Positive

Call changed from Neutral to Positive at $74.95, moderate conviction, October 30, 2026.

Breaks if: The Positive call requires the Attruby commercial ramp to continue. It breaks if reported year-over-year revenue growth decelerates below 50% in either of the next two quarterly filings — broadly through mid-2027 — which would indicate plateau or competitive erosion well before the market's implied peak-sales estimate. A secondary trigger: if annualized free cash flow burn widens beyond $600M in any rolling four-quarter period through year-end 2027, the cash-runway equation deteriorates enough to compress the multiple independent of revenue progress.

Key figures

Market value$14.8B
Revenue, last 12 months$946M
Net income, last 12 months−$574M
Free cash flow, last 12 months−$370M
Price to earningsn/a
Free cash flow yield−2.5%
Dividend yield0.0%
Operating margin−38.5%
Return on equityn/a
Beta to the S&P 5001.00
Volatility, annualized50.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$353M192.6%$-0.42−$44M
June 30, 2026$244M120.4%$-0.78−$72M
March 31, 2026$195M66.8%$-0.84−$197M
December 31, 2025$154M2521.2%$-0.99−$56M
September 30, 2025$121M4318.0%$-0.95−$110M
June 30, 2025$111M4999.9%$-0.95−$81M
March 31, 2025$117M−44.8%$-0.88−$199M
December 31, 2024$6M237.1%$-1.42−$195M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

16 ledger entries and 47 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.